| Previous Close | 2.44 |
| Open | 2.45 |
| Volume | 406,270 |
| Avg. Volume (3M) | 157,422 |
| Market Cap | 35,792,376 |
| Price / Earnings (TTM) | 0.372 |
| Price / Sales | 1.97 |
| Price / Book | 2.55 |
| 52 Weeks Range | |
| Earnings Date | 17 Dec 2025 |
| Profit Margin | -215.24% |
| Operating Margin (TTM) | -242.68% |
| Diluted EPS (TTM) | -0.220 |
| Quarterly Revenue Growth (YOY) | 18.30% |
| Total Debt/Equity (MRQ) | 16.10% |
| Current Ratio (MRQ) | 3.80 |
| Operating Cash Flow (TTM) | -29.08 M |
| Levered Free Cash Flow (TTM) | -7.41 M |
| Return on Assets (TTM) | -49.03% |
| Return on Equity (TTM) | -93.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Veru Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.19% |
| % Held by Institutions | 33.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sheets Smith Investment Management | 30 Sep 2025 | 322,084 |
| Oppenheimer & Co Inc | 30 Sep 2025 | 192,168 |
| Pvg Asset Management Corp | 30 Jun 2025 | 164,737 |
| Summit Financial, Llc | 30 Sep 2025 | 163,852 |
| Ikarian Capital, Llc | 30 Sep 2025 | 142,523 |
| Envestnet Asset Management Inc | 30 Sep 2025 | 76,674 |
| Choreo, Llc | 30 Sep 2025 | 75,468 |
| 52 Weeks Range | ||
| Median | 25.00 (1,021.08%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 18 Dec 2025 | 25.00 (1,021.08%) | Buy | 2.23 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Dec 2025 | Announcement | Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress |
| 10 Dec 2025 | Announcement | Veru to Report Fiscal Year 2025 Financial Results on December 17th |
| 04 Dec 2025 | Announcement | Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop |
| 31 Oct 2025 | Announcement | Veru to Present Two Abstracts at ObesityWeek 2025 |
| 30 Oct 2025 | Announcement | Veru Announces Pricing of $25 Million Public Offering |
| 29 Oct 2025 | Announcement | Veru Announces Proposed Public Offering |
| 23 Sep 2025 | Announcement | Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity |
| 5Y Average Dividend Yield | 0.00% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 28 Apr 2014 | 24 Mar 2014 | 07 May 2014 | 0.07 Cash |
| 27 Jan 2014 | 16 Dec 2013 | 05 Feb 2014 | 0.07 Cash |
| 28 Oct 2013 | 03 Oct 2013 | 06 Nov 2013 | 0.07 Cash |
| 29 Jul 2013 | 15 Jul 2013 | 07 Aug 2013 | 0.07 Cash |
| 28 Jan 2013 | 03 Jan 2013 | 06 Feb 2013 | 0.06 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2014 | 0.140 | 2 | 3.57 |
| 2013 | 0.200 | 3 | 2.35 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |